That’s exactly right. The reconstructed GNBT and NGIO were never conceived to be one trick ponies. That’s what has been attractive about Joe’s vision. Even if they all end up just being workhorses, the sum of all of them will be profitable. If Joe and we investors are lucky, one of them might turn out to be a thoroughbred (although I’m not betting on the vaccine). It’s just taken longer than he planned to get this thing put together. But he’s still working on it, and the vision and concept are still valid. And because of that I bought some more this morning. Go GNBT! Go NGIO!
(3)
(0)
Generex Biotechnology Corp. (GNBTQ) Stock Research Links